Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil.

[1]  Victor E Reuter,et al.  The pathology of renal epithelial neoplasms. , 2006, Seminars in oncology.

[2]  M. Atkins,et al.  Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response. , 2006, Seminars in oncology.

[3]  J. Lam,et al.  Prognostic factors in renal cell carcinoma. , 2006, Seminars in oncology.

[4]  M. Brunelli,et al.  Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision. , 2006, European urology.

[5]  I. Svane,et al.  Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. , 2006, European urology.

[6]  J. Patard.  Dendritic cells for the treatment of metastatic renal cell carcinoma: at a low ebb? , 2006, European urology.

[7]  Antonio Lopez-Beltran,et al.  2004 WHO classification of the renal tumors of the adults. , 2006, European urology.

[8]  W. Scheithauer,et al.  Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial , 2006, British Journal of Cancer.

[9]  N. Rioux-Leclercq,et al.  Understanding the importance of smart drugs in renal cell carcinoma. , 2006, European urology.

[10]  Z. Kırkalı,et al.  Are we really making an advance in the treatment of metastatic renal cell carcinoma? , 2006, European urology.

[11]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[12]  R. Parker,et al.  Histologic Predictors of Renal Cell Carcinoma Response to Interleukin-2-Based Therapy , 2005, Journal of immunotherapy.

[13]  Heung-Kook Choi,et al.  Three-dimensional visualization and quantitative analysis of cervical cell nuclei with confocal laser scanning microscopy. , 2005, Analytical and quantitative cytology and histology.

[14]  S. Signoretti,et al.  Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer , 2005, Clinical Cancer Research.

[15]  N. Rioux-Leclercq,et al.  Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience , 2005 .

[16]  R. Figlin,et al.  Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma , 2003, Cancer.

[17]  S. Campbell,et al.  Metastatic renal cell carcinoma , 2003, Current treatment options in oncology.

[18]  J. Cheville,et al.  Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma , 2003, The American journal of surgical pathology.

[19]  M. Terris,et al.  Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. , 2003, The American journal of pathology.

[20]  R. Motzer,et al.  Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Munshi,et al.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. , 2001, The New England journal of medicine.

[22]  M. Gramatzki,et al.  IL-2 in combination with IFN-αand 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial , 2001, British Journal of Cancer.

[23]  R. Sylvester,et al.  Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial , 2001, The Lancet.

[24]  D. Carbone,et al.  Clinical significance of defective dendritic cell differentiation in cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  R. Fisher,et al.  Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. , 2000, The cancer journal from Scientific American.

[26]  J L Warren,et al.  Rising incidence of renal cell cancer in the United States. , 1999, JAMA.

[27]  A. Novick,et al.  Alterations in NFκB Activation in T Lymphocytes of Patients With Renal Cell Carcinoma , 1999 .

[28]  W. Linehan,et al.  Novel mutations of the MET proto-oncogene in papillary renal carcinomas , 1999, Oncogene.

[29]  R. Fisher,et al.  Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997. , 1997, The cancer journal from Scientific American.

[30]  B. Delahunt,et al.  Classification of renal cell carcinoma , 1997, Cancer.

[31]  S. Steinberg,et al.  Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. , 1996, The cancer journal from Scientific American.

[32]  E. Lopez Hänninen,et al.  Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. , 1993, European journal of cancer.